Drug intelligence / Profile preview

CXG63

Development stage: Preclinical
Lead developer: Chanceon
Modality: Small Molecules
Administration: Inhalation

Overview

CXG63 is a Chanceon inhaled dry-powder triple-combination respiratory medicine comprising an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-2 adrenergic agonist. It is being developed as an improved inhalation product for asthma and chronic obstructive pulmonary disease, intended to combine anti-inflammatory corticosteroid activity with dual bronchodilation and to improve accessibility and bioavailability. ([chancepharmaceuticals.com](https://chancepharmaceuticals.com/cxg63))

Targets

mAChR (Muscarinic acetylcholine receptors)GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on CXG63.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CXG63.

Explore the full profile